A Difficult Balancing Act: Policy Actors’ Perspectives on Using Economic Evaluation to Inform Health-Care Coverage Decisions under the Universal Health Insurance Coverage Scheme in Thailand Yot Teerawattananon1 Steve Russell2 1Health Intervention and Technology Assessment Program (HITAP), Mini

Abstract Background: Only lamivudine has been included for patients with chronic hepatitis B (CHB) in the National List of Essential Drugs (NLED), a pharmaceutical reimbursement list in Thailand. There have also been no economic evaluation studies of CHB drug treatments conducted in Thailand yet. I

Abstract Objectives In Thailand, axillary lymph node dissection (ALND) is the dominant form of treatment for breast cancer, even though the treatment often leaves patients with some degree of arm morbidity. Sentinel lymph node biopsy (SNB) is widely accepted globally as a preferable alternative pr

A cost–utility analysis of alternative drug regimens for newly diagnosed severe lupus nephritis patients in Thailand. Adun Mohara1, Román Pérez Velasco1, Naiyana Praditsitthikorn1,2, Yingyos Avihingsanon3 and Yot Teerawattananon1 1Health Intervention and Technology Assessment Program (HITAP),

The 10th HTAsiaLink Annual Conference is the first physical conference after the pandemic hit for HTAsiaLink network. Under the theme ‘The Role of HTA in the New Normal: Driving the post-COVID health systems through evidence-informed decisions,’ a broad range of discussions were sparked and would co